The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) gapped up by $3.77 today and has $39.84 target or 55.00% above today’s $25.70 share price. The 8 months technical chart setup indicates low risk for the $1.09B company. The gap was reported on Mar, 29 by Barchart.com. If the $39.84 price target is reached, the company will be worth $599.50 million more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 49.59% or $8.52 during the last trading session, hitting $25.7. About 14.96M shares traded hands or 2176.79% up from the average. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 54.56% since August 19, 2015 and is downtrending. It has underperformed by 52.46% the S&P500.
According to Zacks Investment Research, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.”
Alder Biopharmaceuticals Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.